simendan has been researched along with Atrial Fibrillation in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Abella, LMR; Gergs, U; Hoffmann, R; Hofmann, B; Neumann, J | 1 |
| Chen, SA; Chen, YA; Chen, YC; Chen, YJ; Huang, JH; Lin, YK | 1 |
| Dechering, DG; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Kochhäuser, S; Kohnke, A; Reinke, F | 2 |
| Liao, X; Liu, B; Wang, W; Yu, H; Zhou, X | 1 |
| Abacilar, AF; Dogan, OF | 1 |
| Arnold, A; Böning, A; Görlach, G; Grieshaber, P; Lipp, S; Niemann, B; Roth, P; Wilhelm, J; Wollbrück, M | 1 |
| Li, G; Liu, T; Xu, G | 1 |
| Banach, M; Kowalczyk, M; Kozłowski, D; Lip, GY; Mikhailidis, DP; Rysz, J | 1 |
| Tandoğan, I; Yalta, K; Yilmaz, MB; Yontar, OC | 1 |
| Albertsson, P; Boren, J; Grip, L; Hallgren, P; Holmberg, M; Matejka, G; Omerovic, E; Råmunddal, T | 1 |
| Ata, N; Birdane, A; Cavuşoğlu, Y; Demirüstü, C; Göktekin, Ö; Görenek, B; Tek, M; Ünalır, A | 1 |
| Baixas, C; Couderc, P; Delay, M; Galinier, M; Maury, P; Pathak, A; Roncalli, J | 1 |
| Domínguez-Rodríguez, A; Ferrer-Hita, JJ; García-González, MJ | 1 |
2 review(s) available for simendan and Atrial Fibrillation
| Article | Year |
|---|---|
The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.
Topics: Atrial Fibrillation; Coronary Artery Bypass; Humans; Postoperative Complications; Randomized Controlled Trials as Topic; Simendan; Treatment Outcome | 2019 |
Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties.
Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2010 |
2 trial(s) available for simendan and Atrial Fibrillation
| Article | Year |
|---|---|
Levosimendan use decreases atrial fibrillation in patients after coronary artery bypass grafting: a pilot study.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Hydrazones; Incidence; Male; Middle Aged; Pilot Projects; Placebo Effect; Postoperative Complications; Premedication; Pyridazines; Risk Assessment; Simendan; Treatment Outcome; Turkey | 2013 |
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Dobutamine; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Parenteral; Male; Middle Aged; Pyridazines; Risk Factors; Simendan; Tachycardia, Ventricular; Ventricular Premature Complexes | 2010 |
10 other study(ies) available for simendan and Atrial Fibrillation
| Article | Year |
|---|---|
Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium.
Topics: Animals; Atrial Fibrillation; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Mice; Myocardial Contraction; Phosphorylation; Propranolol; Rolipram; Simendan | 2023 |
Levosimendan differentially modulates electrophysiological activities of sinoatrial nodes, pulmonary veins, and the left and right atria.
Topics: Animals; Atrial Fibrillation; Atrial Function; Cardiotonic Agents; Dose-Response Relationship, Drug; Electrophysiological Phenomena; Heart Atria; Humans; Male; Pulmonary Veins; Rabbits; Simendan; Sinoatrial Node | 2018 |
Ranolazine Prevents Levosimendan-Induced Atrial Fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Interactions; Hydrazones; Pyridazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Simendan | 2018 |
Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery - a retrospective analysis.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass; Female; Humans; Hydrazones; Kidney; Male; Middle Aged; Postoperative Complications; Pyridazines; Retrospective Studies; Risk Factors; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Acute infusion of levosimendan enhances atrial fibrillation in an experimental whole-heart model.
Topics: Action Potentials; Animals; Atrial Fibrillation; Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Rate; Hydrazones; Organ Culture Techniques; Pyridazines; Rabbits; Simendan; Time Factors | 2017 |
Levosimendan may prevent postoperative atrial fibrillation through anti-inflammatory and antioxidant modulation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atrial Fibrillation; Humans; Hydrazones; Postoperative Complications; Pyridazines; Simendan | 2009 |
Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Diastole; Echocardiography; Electrocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Stroke Volume | 2010 |
Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.
Topics: Age Factors; Aged; Atrial Fibrillation; Cardiotonic Agents; Chi-Square Distribution; Cohort Studies; Electrocardiography; Female; Heart Arrest; Humans; Hydrazones; Length of Stay; Male; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Pyridazines; Sex Factors; Shock, Cardiogenic; Simendan; Statistics, Nonparametric | 2010 |
Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node:.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Bundle-Branch Block; Cardiotonic Agents; Catheter Ablation; Heart Block; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pacemaker, Artificial; Pyridazines; Simendan | 2004 |
Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases.
Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Fibrillation; Calcium Channel Blockers; Cardiotonic Agents; Electrocardiography; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Middle Aged; Myocardial Infarction; Myocardial Stunning; Pericarditis; Pyridazines; Respiration, Artificial; Shock, Cardiogenic; Simendan; Ventricular Dysfunction, Left | 2005 |